These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 29709968)

  • 41. A recombinant plasmid containing CpG motifs as a novel vaccine adjuvant for immune protection against herpes simplex virus 2.
    He Z; Xu J; Tao W; Fu T; He F; Hu R; Jia L; Hong Y
    Mol Med Rep; 2016 Aug; 14(2):1823-8. PubMed ID: 27357208
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The mechanisms of antiviral immunity induced by a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: clearance of local infection.
    Martin S; Rouse BT
    J Immunol; 1987 May; 138(10):3431-7. PubMed ID: 3033075
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Epigallocatechin gallate inactivates clinical isolates of herpes simplex virus.
    Isaacs CE; Wen GY; Xu W; Jia JH; Rohan L; Corbo C; Di Maggio V; Jenkins EC; Hillier S
    Antimicrob Agents Chemother; 2008 Mar; 52(3):962-70. PubMed ID: 18195068
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Herpes simplex virus type 1 glycoproteins gB, gC and gD are major targets for CD4 T-lymphocyte cytotoxicity in HLA-DR expressing human epidermal keratinocytes.
    Mikloska Z; Cunningham AL
    J Gen Virol; 1998 Feb; 79 ( Pt 2)():353-61. PubMed ID: 9472620
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nasal and skin delivery of IC31(®)-adjuvanted recombinant HSV-2 gD protein confers protection against genital herpes.
    Wizel B; Persson J; Thörn K; Nagy E; Harandi AM
    Vaccine; 2012 Jun; 30(29):4361-8. PubMed ID: 22682292
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Induction of protective immunity with antibody to herpes simplex virus type 1 glycoprotein H (gH) and analysis of the immune response to gH expressed in recombinant vaccinia virus.
    Forrester AJ; Sullivan V; Simmons A; Blacklaws BA; Smith GL; Nash AA; Minson AC
    J Gen Virol; 1991 Feb; 72 ( Pt 2)():369-75. PubMed ID: 1704412
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Recombinant vaccinia virus LC16m0 or LC16m8 that expresses hepatitis B surface antigen while preserving the attenuation of the parental virus strain.
    Morita M; Suzuki K; Yasuda A; Kojima A; Sugimoto M; Watanabe K; Kobayashi H; Kajima K; Hashizume S
    Vaccine; 1987 Mar; 5(1):65-70. PubMed ID: 3554809
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Improved recombinant LC16m0 or LC16m8 vaccinia virus successfully expressing hepatitis B surface antigen.
    Watanabe K; Kobayashi H; Kajiyama K; Morita M; Yasuda A; Gotoh H; Saeki S; Sugimoto M; Saito H; Kojima A
    Vaccine; 1989 Feb; 7(1):53-9. PubMed ID: 2718607
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intramuscular vaccination of guinea pigs with the live-attenuated human herpes simplex vaccine VC2 stimulates a transcriptional profile of vaginal Th17 and regulatory Tr1 responses.
    Stanfield BA; Rider PJF; Caskey J; Del Piero F; Kousoulas KG
    Vaccine; 2018 May; 36(20):2842-2849. PubMed ID: 29655629
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Glycosylated and nonglycosylated complement control protein of the lister strain of vaccinia virus.
    Meseda CA; Kuhn J; Atukorale V; Campbell J; Weir JP
    Clin Vaccine Immunol; 2014 Sep; 21(9):1330-8. PubMed ID: 25030055
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Stability of recombinant vaccinia virus LC16m0 or LC16m8: preserved laboratory attenuation markers and conserved expression of inserted HBsAg gene.
    Watanabe K; Morita M; Kojima A
    Vaccine; 1989 Dec; 7(6):499-502. PubMed ID: 2609725
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Vaccinia Virus LC16m8∆ as a Vaccine Vector for Clinical Applications.
    Kidokoro M; Shida H
    Vaccines (Basel); 2014 Oct; 2(4):755-71. PubMed ID: 26344890
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Generation of recombinant vaccinia virus and analysis of virus-induced cell death.
    Liu Z; Kang K; Ka-Ming Chan F
    STAR Protoc; 2021 Dec; 2(4):100871. PubMed ID: 34661172
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of Serial Passage on the Pathogenicity and Immunogenicity of Vaccinia Virus LC16m8 Strain.
    Eto A; Yamamoto N; Kanatani Y
    Biology (Basel); 2021 Nov; 10(11):. PubMed ID: 34827150
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety of attenuated smallpox vaccine LC16m8 in immunodeficient mice.
    Yokote H; Shinmura Y; Kanehara T; Maruno S; Kuranaga M; Matsui H; Hashizume S
    Clin Vaccine Immunol; 2014 Sep; 21(9):1261-6. PubMed ID: 24990910
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The primary production of an infectious recombinant Herpes Simplex Virus vaccine.
    O'Keeffe R; Johnston MD; Slater NK
    Biotechnol Bioeng; 1998 Feb; 57(3):262-71. PubMed ID: 10099202
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Developing an asymptomatic mucosal herpes vaccine: the present and the future.
    Dasgupta G; Nesburn AB; Wechsler SL; BenMohamed L
    Future Microbiol; 2010 Jan; 5(1):1-4. PubMed ID: 20020824
    [No Abstract]   [Full Text] [Related]  

  • 58. A two-dose viral-vectored
    Yamamoto Y; Fabbri C; Okuhara D; Takagi R; Kawabata Y; Katayama T; Iyori M; Hasyim AA; Sakamoto A; Mizukami H; Shida H; Lopes S; Yoshida S
    Front Immunol; 2024; 15():1372584. PubMed ID: 38745665
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Construction of a recombinant vaccine expressing Nipah virus glycoprotein using the replicative and highly attenuated vaccinia virus strain LC16m8.
    Watanabe S; Yoshikawa T; Kaku Y; Kurosu T; Fukushi S; Sugimoto S; Nishisaka Y; Fuji H; Marsh G; Maeda K; Ebihara H; Morikawa S; Shimojima M; Saijo M
    PLoS Negl Trop Dis; 2023 Dec; 17(12):e0011851. PubMed ID: 38100536
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.